Corti

Corti, the Copenhagen clinical-AI company, runs across about 250,000 patient interactions a day. Customers include the UK’s NHS and a long list of European emergency-dispatch and primary-care operators. The last priced round was a $60M Series B in 2023 at a $260M valuation. CEO Andreas Cleve told CNBC at the end of December 2025 that Corti will eventually IPO but not in 2026, calling private markets still “very appealing.”

The 2025 product story was a deliberate move away from running clinical AI inside the major US-anchored hyperscalers. In July 2025 Corti launched what it calls Europe’s first sovereign healthcare AI cloud, designed to run on any cloud or on-prem and portable off any single vendor. The anchor partner is Voicepoint, Switzerland’s leading medical-documentation provider. Corti also released a clinical-grade Danish speech-to-text model and three healthcare-specialised foundation models trained exclusively on medical data.

The pitch is sharper than it looks. Corti is arguing that hyperscaler-managed AI is a regulatory liability under the EU AI Act in clinical settings, and that compliance, not capability, is the wedge to displace incumbent ambient-scribe vendors that ride US-resident clouds. That is a different bet from what Microsoft Nuance and Suki are running. It puts Corti in direct conversation with European hospital procurement teams that have been quietly reassessing their AI vendor lists since the Act came in.

If the bet is right, the next funding round looks more like a strategic round than a generalist VC one. Reading across to the rest of the directory, Sidekick Health is the only other Nordic healthtech operating at a comparable European procurement layer; Corti’s regulatory-as-wedge thesis is the one most worth tracking for anyone betting on the sovereignty layer of European AI.